Related Experiment Video
Updated: Feb 17, 2026
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer
Iñaki Comino-Mendez1, Nicholas Turner2,3
1Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom.
Detecting residual disease with circulating tumor DNA (ctDNA) analysis accurately predicts relapse in early-stage lung cancer patients. This advancement offers new treatment strategies for cancer care.
Area of Science:
- Oncology
- Molecular Diagnostics
- Cancer Genomics
Background:
- Circulating tumor DNA (ctDNA) analysis is an emerging tool in cancer research.
- Accurate detection of minimal residual disease (MRD) is crucial for guiding treatment decisions.
Purpose of the Study:
- To evaluate the predictive value of ctDNA analysis for relapse in early-stage lung cancer patients.
- To explore the potential of ctDNA detection for informing cancer treatment strategies.
Main Methods:
- Analysis of ctDNA in patient samples after primary treatment for early-stage lung cancer.
- Correlation of ctDNA detection with clinical outcomes, specifically relapse.
Main Results:
- ctDNA analysis demonstrated high accuracy in predicting relapse after treatment.
- Detection of residual disease using ctDNA is a significant indicator of future cancer recurrence.
Conclusions:
- ctDNA analysis is a powerful tool for detecting minimal residual disease in early-stage lung cancer.
- This technology can improve patient stratification and inform personalized treatment strategies to prevent relapse.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019